OncoMatch/Clinical Trials/NCT06931626
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Is NCT06931626 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including NMS-03305293 and Temozolomide for small cell lung cancer.
Treatment: NMS-03305293 · Temozolomide — This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with TMZ.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
measurable disease as defined by RECIST v1.1 (radiologically measured by the Investigator)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — front-line
must have failed prior front-line platinum-based therapy including immune therapy with relapse within 6 months
Must have received: immune therapy — front-line
must have failed prior front-line platinum-based therapy including immune therapy with relapse within 6 months
Must have received: tarlatamab (tarlatamab) — post-relapse
failed tarlatamab therapy, if available and appropriate
Cannot have received: wide-field radiotherapy
Patients with prior wide-field radiotherapy (RT) affecting at least 20 percent of the bone marrow
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
- Tennessee Oncology, PLLC · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify